Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report

RATIONALE: Currently, the 5-year survival rate remains poor for patients with metastatic colorectal cancer (mCRC), and the purpose of therapy is to prolong survival while maintaining the quality of life. Trifluridine/tipiracil, an oral drug combining trifluorothymidine and a thymidine phosphorylase...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Lin, Liu, Kao-Lang, Lin, Been-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581032/
https://www.ncbi.nlm.nih.gov/pubmed/33120790
http://dx.doi.org/10.1097/MD.0000000000022780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581032/
https://www.ncbi.nlm.nih.gov/pubmed/33120790
http://dx.doi.org/10.1097/MD.0000000000022780

Ejemplares similares